Company Update (NYSE MKT:ISR): IsoRay, Inc.’s Cesium-131 Selected By Chicago Prostate Cancer Center For Use In The Launch Of Study Of Prostate Cancer Treatment

IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, announced that Dr. Brian J. Moran, Director of Chicago Prostate Cancer Center in Westmont, Illinois, has initiated a study of focal prostate cancer treatment using Cesium-131 brachytherapy.

Focal therapy is treatment directed solely at the malignancy and its immediate surrounding tissue, rather than the entire gland or organ that is involved. The goal of focal therapy for prostate cancer is to eliminate the targeted cancer while sparing men the side effects that often come with whole gland treatment.

Dr. Moran stated, “I think the mindset of prostate cancer treatment until today has been all or none. In other words, one size fits all and you do either whole gland radiation or surgical removal. The medical community has been very slow to evaluate the concept of focal therapy for the treatment of prostate cancer.”

Dr. Moran plans to build on observations derived from his previous focal cases and further noted, “Our initial experience with focal therapy was patient-driven by individuals who were deciding between active surveillance and full gland treatment. We initially embarked on this approach approximately 10 years ago. Over time, it became very apparent that the results were encouraging. Cancer control rates were excellent and toxicity was negligible. This should be the goal of any cancer therapy: to eradicate the malignancy while not impairing quality of life. Naturally, patient selection is of paramount importance when choosing focal therapy to treat prostate cancer. For the past 10 years, we have been offering a transperineal mapping biopsy that is very comprehensive. The information using this technique allows us to identify the exact location of the cancer within the prostate.”

Dr. Moran’s focal study will employ Cesium-131 radioactive seed implantation to the affected area of the prostate. Dr. Moran further noted, “We chose Cesium-131 due to its generous energy and homogeneous dose. This minimizes potential cold spots and offers adequate margin to the area being treated.”

The study is currently open for enrollment, and will analyze patterns of response in a structured fashion.

IsoRay Chairman and CEO Dwight Babcock commented, “We are pleased that a growing number of leading physicians and medical institutions are embracing the use of Cesium-131 in fighting cancers throughout the body. We continue to receive inquiries from new physicians and institutions based on recently released peer reviewed publications reporting on the successes of using Cesium-131. Medical professionals rely on these publications to further their practice and learn about new leading edge products.”
IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life. (Original Source)

Shares of IsoRay Inc opened today at $1.51 and are currently trading down at $1.5. ISR has a 1-year high of $3.79 and a 1-year low of $1.22. The stock’s 50-day moving average is $1.67 and its 200-day moving average is $1.55.

On the ratings front, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ISR, with a price target of $5, in a report issued on May 21. The current price target represents a potential upside of 233.3% from where the stock is currently trading.

According to, Kolbert has a total average return of 1.5%, a 42.0% success rate, and is ranked #1566 out of 3681 analysts.

IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts